Prostate Cancer Clinical Trial
Official title:
A Multi-Center Prospective Single Arm Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men achieving trifecta status (no erectile dysfunction, leak-free pad-free continence, cancer control). However, these trials have involved small numbers of patients with men selected for good baseline function. A multi-centre prospective trial within a larger cohort of men that better represents the patient population with prostate cancer (external validity) is required.
Verification of a new therapy as favourable, or equivalent, in outcome to 'standard' care is
ideally sought through comparison with another matched control group. Randomised controlled
trials (RCTs) offer the best method for minimising systematic bias and revealing the true
effect of an intervention or drug. However, RCTs involving treatments of localised prostate
cancer have had a historically poor patient uptake, as the reference 'gold' standard of care
is not known. In addition, RCTs are expensive to run and involve huge infra-structural
support. A number of trials in the USA have been forced to close due to lack of recruitment.
The ProStart trial in the UK has also had to close for the same reason. It has been
acknowledged by the Food and Drug Agency in the USA that comparative randomized trials will
be problematic in this area due to lack of physician and patient equipoise. A randomized
trial may be feasible if a pragmatic design is adopted but prior to acceptance of such a
design, the number of centres with expertise in this complex intervention (mp-MRI, TTPM,
focal HIFU) will need to be increased.
Observational studies are a commonly used alternative to ascertain the effectiveness of a
treatment. They are used to observe a treatment effect in a selected group of patients who
are presumed to derive benefit from the treatment given. Although methodologically not as
robust, and therefore prone to bias, they have some benefits over RCTs. The principal ones
are those of enhanced external validity (many patients do not wished to be randomised and
therefore refuse participation), and more rapid accrual compared to a randomised design. For
this reasons, a single arm medium term follow-up cohort intervention study has been designed.
At the time of writing the safety and tolerability aspects of focal therapy by HIFU are known
as a result of the Phase I/II studies carried out at UCLH. The results have been presented
and exist in the public domain in abstract form but have not yet been published (presented in
tables above). These early studies were powered to detect a change in the proportion of men
who could obtain an erection sufficient for penetration compared to their status prior to
their treatment. The very low event rate for both erectile dysfunction and incontinence
indicates that the 'proof of concept' has been demonstrated for focal therapy. Moreover, we
can be relatively confident that, in expert hands, focal HIFU is safe. Therefore, a
multi-centre study is now required involving a larger group of patients for the following
reasons:
1. To evaluate medium term cancer control using histological parameters. Stage two of INDEX
will evaluate conversion to radical and systemic therapies and link men to national
databases to determine survival in 5 and 10 years.
2. To confirm that focal therapy can lead to low rates of genitourinary and rectal toxicity
and minimal impact on quality of life within a large and more representative cohort of
patients (greater precision around outcome measures).
3. To demonstrate that the skills (characterization through template prostate mapping and
MRI as well as the treatment related skills) acquired by the team at UCLH are indeed
transferable to other providers.
4. To calculate costs of care and to model potential cost-effectiveness in comparison to
alternative therapies. If this single arm intervention study demonstrates acceptable
outcomes to support the findings of the Phase I/II studies, it is anticipated that this
preliminary study will lead onto a Phase III evaluation of focal therapy, prior to more
widespread use of this technology.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |